Project Grant R21AI190243
Award Date 9/4/25
Completion Date 8/31/27
Dollars Obligated $458K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
- This $300,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel vaccine candidates for cryptosporidiosis, a leading cause of diarrhea and malnutrition in children in low- and middle-income countries. The grantee, Immport Therapeutics Inc. (doing business as Antigen Discovery Inc.), will formulate cryptosporidium proteins and a mucosal...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel multivalent mucosal vaccines for human noroviruses. The total funding is $798,173 with a project period from May 1, 2025 to April 30, 2030. The key products and services to be delivered include: 1) Developing multivalent, live-vectored mucosal norovirus vaccines using FDA-approved rotavirus (RotaTeq)...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $242,250.00 to researchers at the University of Virginia to develop a vaccine against cryptosporidiosis, a common cause of diarrheal disease in sub-Saharan Africa and Asia. The goal is to create a liposomal vaccine formulation that stimulates both cellular and humoral immunity targeting the extracellular and intracellular life stages of the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,968 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Viva Viral Vaccines, Inc. to develop a broad-spectrum, multivalent vaccine platform for pandemic and seasonal influenza. The platform leverages innovations in the production of influenza neuraminidase (NA) proteins in mammalian cells, enabling the development of VLP-based vaccines that can provide broad heterologous...
- This Project Grant award of $233,528 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research, supports a systems analysis of immune responses to norovirus infection in a human challenge model. The research aims to delineate the transcriptomic responses in human peripheral blood and stool samples collected from volunteers before and after controlled infection with different strains and doses of norovirus. The goal is to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $593,021 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to The Washington University in Missouri. The grant supports a mechanistic investigation of the rotavirus non-structural protein NSP6 and its role in counteracting host defenses. Specifically, the research aims to: 1) define the key amino acids within NSP6 responsible for secretion and chemoattractant binding, and 2)...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $433,175 to develop a mosaic mRNA vaccine to prevent hand, foot and mouth disease (HFMD). The goal is to create a broadly protective vaccine that can address the diverse viral strains that cause HFMD, which is primarily caused by human enterovirus serotype A viruses and can lead to severe complications like viral...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $502,248 Project Grant to the University of Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to understand how human intestinal epithelial cells produce type III interferons to combat rotavirus infection, a leading cause of viral gastroenteritis deaths worldwide. Specifically, the research aims to investigate the signaling pathways, such as RIG-like receptors...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $308,669 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to Vishenary, LLC to develop a novel vaccine with broad efficacy against nontypeable Haemophilus influenzae (NTHI) strains following influenza A virus (IAV) infection. The project aims to create a vaccine candidate consisting of a conserved NTHI protein (Protein 0259) and the FDA-approved histone deacetylase inhibitor...